Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[L11416] It is also available in combination with [metformin],[L11419] [glimepiride],[L11422] or [alogliptin][L11425] for the same indication.
Marketing Status approved; investigational
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 0093-7271; 50090-4586; 53002-2757; 61919-781; 64764-151; 68071-5210; 68382-308; 71335-1333; 71335-1385; 43547-428; 71610-495; 72189-105; 0781-5421; 0781-5422; 0904-7090; 50090-4556; 50090-6412; 53002-2755; 68071-5245; 68788-7514; 70518-2129; 71335-1759; 71335-1298; 16714-647; 33342-054; 57237-220; 57237-221; 68382-306; 68788-7989; 70518-2609; 70771-1021; 71335-1659; 0781-5420; 11532-0012; 16714-645; 0093-7272; 64764-301; 64764-451; 70771-1023; 71335-1343; 33342-055; 43547-427; 57237-219; 68071-2886; 68071-4964; 0904-7096; 16729-020; 50090-4605; 70518-2431; 70771-1022; 72189-293; 16714-646; 60687-391; 68788-7511; 71335-1137; 16729-021; 0093-7273; 43547-426; 68071-2264; 68382-307; 11532-0011; 11532-0013; 16729-022; 33342-056; 53002-2756
UNII X4OV71U42S
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vertigo17.02.12.002; 04.04.01.003--
Visual acuity reduced17.17.01.011; 06.02.10.012--
Visual impairment06.02.10.013--Not Available
Volume blood increased13.11.02.001--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Lacunar infarction24.04.06.009; 17.08.01.0160.000086%Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.011--Not Available
Lymphatic disorder01.09.01.003--Not Available
Diastolic dysfunction02.04.02.0220.000189%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000086%
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Hepatic enzyme decreased13.03.04.027--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.000601%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation11.09.01.001; 23.11.01.002--Not Available
Ischaemia24.04.02.004--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Cystitis noninfective20.03.02.0010.000086%
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages